This site is presented as a single continuous document because JavaScript is unavailable.
Private Investment Group · United Kingdom
Building the new era of superior dental care.
DentLuxue Holdings acquires premium independent dental practices across the United Kingdom and integrates them, with rigour, into a single clinical and operational platform — backed by disciplined capital and genuinely transformative technology.
0.00bn
UK high-street dentistry, 2023/24
£12.16bn, up 9.2% year on year. LaingBuisson, Dentistry UK, 7th ed., Sept 2025.
0%
Of that market is private-pay
£8.4bn private against £3.78bn NHS; private-pay grew £965m in the year.
0%
Of UK adults saw an NHS dentist
18.8m adults in the 24 months to 31 March 2026. NHSBSA, published 27 Aug 2026.
0→0%
Corporate share of dental transactions
7% of 2025 completions; c.20% of the 2026 live pipeline. Christie & Co, Jan 2026.
The Operating Model
One group, built around the practice.
Not a holding pen for assets. A single platform in which clinical identity is preserved and everything behind it is consolidated.
Premium independent practices
Established clinical reputations, loyal private patient bases, principals with no obvious successor.
Established small groups
Two to ten sites with proven management and consistent standards, constrained by capital.
DentLuxue Holdings
The Platform
Capital & corporate discipline
Underwriting, financing, governance and reporting held to institutional standard from the first acquisition.
Clinical & digital architecture
Shared clinical governance, digital workflow, diagnostics and data — deployed as infrastructure, not as a bolt-on.
The output
A unified network delivering clinical excellence at scale
The Market
A £12 billion market, and a supply side that has not caught up.
Demand has moved decisively private. Ownership has not consolidated with it. That gap is the opportunity, and it is measurable.
The full thesisWho We Serve
Three constituencies. One structure.
Practice principals
A considered exit with genuine continuity for your team and your patients — structured around what you actually want from the transition, not around a template.
How we acquireClinical partners
Participation in the group itself rather than in a single site — the value you help create across the whole platform, not only within your four walls.
Join usInstitutional counterparties
Lenders, advisers and intermediaries dealing with a board that has closed this transaction type before, and governance built to institutional standard from day one.
Meet the boardBoard, Executive & Non-Executive
A cadre of operators, not a list of advisers.
Between them: leadership of Portman Dental Care, myDentist and IDH, Dentex, the IDH Group, Wolters Kluwer, RWS Holdings, HSBC, UBS, Citigroup and IBM.
Founders & Board
Four PrincipalsMr Waheed Qaiser
Co-Founder & Chairman
Three decades as Chairman, Chief Executive and Managing Director across the world’s principal financial centres; investment banking, M&A, asset and wealth management.
Mr Andrew Brode
Co-Founder & Vice Chairman
Chartered accountant; former CEO of Wolters Kluwer (UK) PLC. Acquired and scaled RWS Holdings PLC, Learning Technologies Group plc and GRC Group International PLC.
Mr Joel Pall
Founding Principal
Founder of DentLuxue. Identified UK private dentistry as a market ripe for consolidation, professionalisation and a genuinely differentiated service model.
Mr Manvedeep Singh
Co-Founder & Head of M&A
British investor across healthcare, technology and finance; interests spanning care villages, residential care, home care, cybersecurity and artificial intelligence.
Executive Team
Five OfficersMr Andy Sloan
Chief Executive Officer
Statutory board director of Portman Dental Care through its most active acquisition phase; board signatory on more than 120 practice acquisitions. Latterly MD, Dental EMEA at Agilio Software.
Mr Lutfi Talib
Chief Financial Officer
Partner of Maxim Corporate Finance LLP; 35 years across audit, corporate finance and tax. FCCA, CPA (Australia), MCIS; co-founder of Chancery Capital Markets plc.
Mr Steve Williams
Chief Operating Officer
GDC-registered dentist; over ten years at board level as Clinical Director at myDentist and COO at Together Dental. Oversight of more than 350 completed acquisitions.
Dr Jason Bedford
Chief Clinical Officer
GDC Specialist Register in Endodontics since 2000. Executive experience across the IDH Group, Dental Directory and Dentex; co-founder of Today’s Dental and founder of D2D Endo.
To be confirmed
Chief Legal Officer
Appointment in progress. This entry will be updated when the appointment is completed and filed.
Non-Executive Team
Three DirectorsMs Lindsey Walker
Non-Executive Director
Former COO of IDH Ltd, parent of myDentist, accountable for £300m+ of NHS contract value to 5m patients; grew the estate from 60 to over 600 clinics.
Mr Jonathan Loretto
Non-Executive Director
Global commercial and technology leader. Chief Growth Officer at GFT; previously global security lead at HSBC Digital and accountable Partner at IBM for the European Blockchain Delivery Centres.
To be confirmed
Non-Executive Director
Appointment in progress. This entry will be updated when the appointment is completed and filed.
Do you own a practice you have spent a career building?
A confidential first conversation, under NDA, with no obligation on either side.
The Group
A disciplined platform for a fragmented market.
DentLuxue Holdings Limited is a private investment group established to capitalise upon a structural inflection point in the United Kingdom’s private dental sector, uniting internationally experienced professionals across healthcare, mergers and acquisitions, technology, institutional capital markets and professional services.
Mandate
What we do.
Our mandate is threefold: to acquire premium independent dental practices; to integrate them, with rigour, into a unified clinical and operational platform; and to deploy technology that is genuinely transformative rather than cosmetic — the operating architecture upon which category leadership is built and sustained.
The opportunity rests on durable structural forces. Sustained NHS constraint has catalysed a lasting shift toward private care while rising patient expectations broaden the market, with particular momentum in higher-margin specialities. Against that demand, the supply side remains conspicuously fragmented: independent operators face regulatory burden, staffing constraint and the capital cost of modernisation, and comparatively few can fund all three at once.
Through horizontal and vertical integration we intend to deploy digital platforms, robotics and applied artificial intelligence to drive measurable improvement in clinical outcomes, operational efficiency and patient experience — clinical excellence delivered in environments of understated luxury.
The Group’s stated objective is to reach a turnover of £100 million or more by 2030. That is an objective, not a forecast; it depends on acquisitions that have not yet been made and financing that has not yet been committed.
Principles
What we hold to.
Clinical primacy
Every acquisition is judged first on the quality of care it delivers. A practice that fails on clinical grounds is not rescued by its arithmetic.
Identity preserved
Each practice keeps the clinical identity its principal built. What consolidates is the infrastructure behind it, not the name above the door.
Operational discipline
Value is created by hands-on stewardship after completion, not by the announcement of a transaction.
Ownership, not custody
The Group is assembled to be held and compounded, not dressed for a rapid onward sale.
Governance
Committees and charters.
Institutional discipline by design. Each committee operates to a defined mandate as the Group’s governance matures alongside its estate.
- Executive Committee
- Day-to-day management and strategic direction of the Group.
- Investment Committee
- Underwrites all material acquisitions against defined criteria, and owns post-acquisition monitoring against the case on which each was approved.
- Clinical Governance Committee
- Sets and safeguards clinical standards, quality and patient safety across every practice in the Group. Chaired by the Chief Clinical Officer.
- Audit & Risk Committee
- Financial integrity, internal control, and the Group’s relationship with its external auditors.
- Nomination & Remuneration Committee
- Succession, board composition, and the alignment of remuneration with long-term value creation.
- Conflicts & Compliance
- Maintains the conflicts register and oversees compliance with the regulatory perimeter within which the Group operates.
The Group is at an early stage. Committee mandates are established in principle; formal charters are adopted, and memberships appointed, as the corresponding activity commences.
Leadership
Twelve seats. Nine filled.
The Board and executive team assembled for DentLuxue draws on the leadership of Portman Dental Care, myDentist, IDH, Dentex and Together Dental, and on capital markets experience at UBS, HSBC and Citigroup. Two appointments remain open and are identified as such.
Founders & Board
Co-Founders and PrincipalsMr Waheed Qaiser
Co-Founder & Chairman
A senior financial services executive — having served as Chairman, Chief Executive and Managing Director — with over three decades of achievement across the world’s principal global financial centres. His expertise spans investment banking, mergers and acquisitions, asset and wealth management, and corporate finance.
Mr Qaiser played a pioneering role in the establishment and promotion of Islamic banking in Europe, commencing in 1998 as Lead Founder of the first Islamic bank in the United Kingdom. He has led management teams at QCC, Chapterhouse, Pairstech, IBB, IIBU, UBS, HSBC and Citigroup.
A founding member of the Bank of England Working Party on Islamic Mortgages, he was instrumental in securing an amendment to the British stamp duty regime abolishing the double imposition on Islamic mortgage structures. He further served as a Founding Member of the UK Technical Group at the Securities Investment Institute, contributing to the development of the Islamic Finance Qualification in corporate finance. He co-authored a definitive text on Islamic retail banking and finance published by Euromoney, London.
Mr Andrew Brode
Co-Founder & Vice Chairman
An accomplished entrepreneur and investor. He qualified as a Chartered Accountant and began his career with Arthur Andersen and Rothschilds, before moving into business publishing as Managing Director of Croner Publications, which he built up and sold to Wolters Kluwer. He later became Chief Executive of Wolters Kluwer (UK) PLC, expanding the business to UK sales of £80 million.
He went on to acquire and scale several market-leading businesses including Eclipse Publications, RWS Holdings PLC, Learning Technologies Group plc and GRC Group International PLC, and has held senior roles with Axco Insurance Information Services and Electric Word plc — driving growth and successful exits across multiple industries.
Mr Joel Pall
Founding Principal
Jóel Páll Viðarsson, known professionally as Joel Pall, began his career in the most unpretentious of circumstances — a formative grounding that instilled a deep appreciation for operational discipline, service excellence and the value of purposeful endeavour. Through a succession of increasingly senior responsibilities he became a steward of purposeful growth, driven by an enduring commitment to converting opportunity into lasting value.
With broad experience across diverse industries and international markets, Mr Pall elected to direct his expertise toward the United Kingdom and, specifically, toward private dentistry — a market he identified as ripe for consolidation, professionalisation and the application of a genuinely differentiated service model.
His vision is unambiguous: to establish a dental brand capable of delivering a standard of clinical and hospitality experience that transcends contractual obligation. To realise it, he founded DentLuxue, with the stated aim of transforming a fragmented and underserved market into a single thriving enterprise built on clinical excellence, partnership and long-term value creation.
Mr Manvedeep Singh
Co-Founder & Head of Mergers and Acquisitions
Manvedeep Singh, known professionally as Manav, is a British-based businessman and investor whose experience extends across healthcare, technology, finance and adjacent sectors. Endowed with global interests and a keen strategic mind, he combines foresight with measured and decisive execution.
Mr Singh’s present interests encompass care villages, residential care homes, home care services, e-commerce ventures, cybersecurity, professional service firms and artificial intelligence businesses, among other endeavours. He brings to each engagement a rigorous approach to capital deployment, operational oversight and value creation, and serves as Founder, Adviser and Non-Executive Director to various enterprises.
Executive Team
Officers of the GroupMr Andy Sloan
Chief Executive Officer
One of UK dentistry’s most experienced acquisition and growth leaders, with more than fifteen years at the centre of the sector’s consolidation. His career spans hospitality, banking and accountancy before dentistry — a grounding that shaped a commercial philosophy built on service excellence, financial discipline and operational rigour.
Mr Sloan served as a statutory board director of Portman Dental Care through the most active phase of its acquisition-led growth, sitting as board signatory on more than 120 practice acquisitions and personally leading between thirty and forty transactions end to end — from origination and negotiation through due diligence, completion and integration. His sector experience further includes senior leadership roles at Henry Schein and DBG, and most recently Managing Director, Dental EMEA at Agilio Software, whose platforms serve more than 5,000 practices and nineteen of the twenty largest dental groups in the United Kingdom.
Beyond his executive career he is Executive Editor of Dentist Times, chairs the dental stream of the UK Healthcare Summit and the Dentist Times Owners Club programme, and is the author of The Accidental Dental Strategist, publishing in 2027. As Chief Executive of DentLuxue he leads on the principle that the best dental acquisitions are partnerships, not purchases.
Mr Lutfi Talib
Chief Financial Officer
A partner of Maxim Corporate Finance LLP and a financial services entrepreneur with a career spanning 35 years. He began in accounting at Ernst & Whinney (now Ernst & Young) before specialising in financial services across successive UK appointments, providing business consultancy to investment houses and property companies and formulating pension scheme and corporate structures for overseas companies.
In 2001 he joined Shaw Walker as Audit Partner, and from 2004 established Ashfields — subsequently rebranded McMillan Woods — focusing on business consultancy, corporate finance, audit, tax and accounts. He is co-founder of Montagu Financial Services (2005), Maxim Corporate Finance LLP (2007), Chancery Capital Markets plc (2008) and PP Investco Limited (2009).
He holds an MBA from Middlesex University and a degree in International Business and Management of Companies from Pace University. He is a Fellow of the Association of Chartered Certified Accountants, a Certified Public Accountant in Australia, a Member of the Institute of Singapore Chartered Accountants, a Member of the Chartered Institute for Securities and Investment, a Member of the Chartered Institute of Management, and a Fellow of the Royal Society of Arts.
Mr Steve Williams
Chief Operating Officer
Stephen Williams, known professionally as Steve, is an experienced dental leader with more than three decades of clinical, operational and private equity expertise. A qualified dentist with active GDC registration, he has led large multisite organisations, driven significant commercial growth and built high-performing teams across the United Kingdom’s dental sector.
He is one of few dentists in the UK to have held board positions in private equity backed dental corporates in both a clinical and an operational role. Serving for over ten years at board level — as Clinical Director at myDentist and Chief Operating Officer at Together Dental — his tenure included major improvements in governance, regulatory compliance and clinician retention, driving organic growth, leading successful integrations and building external reputation. He has had oversight of over 350 completed acquisitions and is an established consultant advising investors on operational and clinical due diligence in the dental sector.
Dr Jason Bedford
Chief Clinical Officer
An experienced dental clinician, entrepreneur and executive leader with more than 30 years’ experience across clinical practice, dental business, education and the wider UK dental sector. He qualified from the University of Manchester in 1992 and, following five years in general dental practice and a further three years of postgraduate training, was admitted to the General Dental Council Specialist Register in Endodontics in 2000.
His executive and commercial experience spans the IDH Group, Dental Directory and Dentex, and he was a co-founder of Today’s Dental. In 2006 he founded D2D Endo, an online endodontic education and supply business which became a market leader in its sector, serving dental professionals in 44 countries and training more than 8,000 dentists; it was acquired by Sendoline AB in 2011.
As Chief Clinical Officer he is responsible for ensuring clinical excellence and patient care remain central to the Group’s strategy as it grows: building high-performing clinical teams, supporting clinicians and practice owners, developing scalable clinical systems, and creating an environment in which practices can grow without losing the individual culture, professional standards and patient relationships that made them successful.
To be confirmed
Chief Legal Officer
The Chief Legal Officer appointment is in progress. This entry will be completed when the appointment is executed and, where required, filed at Companies House.
Non-Executive Team
Independent OversightMs Lindsey Walker
Non-Executive Director
A C-suite director experienced in both private and public sectors, with a background comprising national retail roles, director positions within children’s services providers, NHS-affiliated primary care, and various transformational roles.
As Chief Operating Officer of IDH Ltd, the parent company of myDentist, she was accountable for the delivery of £300m+ of NHS contract value nationally to 5 million patients, together with the operation and integration of all practices, increasing the estate from 60 to over 600 clinics. She also established a complete operations team to facilitate this, providing a blueprint across the industry.
As Non-Executive Director of DentLuxue she provides independent oversight, strategic counsel and rigorous challenge across the business, assisting in the development of an acquisition-led growth model.
Mr Jonathan Loretto
Non-Executive Director
A global commercial and technology leader with experience advising firms across Europe, North America and Asia Pacific through their transformation from traditional enterprises to innovative and agile businesses. He is an advisor to several charitable boards on technology utilisation, business operations and market engagement.
As Chief Growth Officer at GFT he managed the end-to-end restructure of the business from sales through to the professional services unit, resulting in a doubling of revenue and tripling of profits over two years. Prior to GFT he led security globally at HSBC Digital, creating a foundational security architecture and flexible modular authentication platform that reduced operational complexity across 38 markets. At IBM he was the accountable Partner for the redevelopment of the European Blockchain Delivery Centres, enabling the construction of large consortia including WeTrade, TradeLens, LedgerConnect and Vinturas, delivering £100m in ARR, and led the global recovery of Maersk’s IT systems in eight weeks following the NotPetya attack.
He holds an MSc in Information Systems and Management and is a former lecturer at Warwick Business School.
To be confirmed
Non-Executive Director
The third Non-Executive appointment is in progress. This entry will be completed when the appointment is executed and, where required, filed at Companies House.
Biographies are published as furnished by each individual. Statutory directorships and persons with significant control are a matter of public record at Companies House under registration number 17448083; the register, not this page, is determinative of who holds office at any given time.
Acquisition Strategy
We work with a small number of principals each year.
At a pace that respects the business being sold and the people inside it. Every process begins with a confidential conversation and a mutual non-disclosure agreement, and proceeds only if both sides want it to.
Why Now
Four shifts, converging.
- Succession without successors
- A generation of independent principals is approaching retirement. Practice values have outpaced what an individual associate can fund alone, so the internal succession that once absorbed these businesses no longer clears.Structural
- Demand has moved private
- Private-pay dentistry is now 69% of the UK high-street market at £8.4bn, and grew £965m in a single year. NHS access remains constrained: 40% of adults were seen in the 24 months to 31 March 2026.Measured
- The corporate window is reopening
- Corporate buyers accounted for only 7% of completed dental transactions in 2025, but around 20% of the 2026 live pipeline. Vendors who transact now still choose their acquirer; in a hotter market they are chosen.Timing
- A widening capability gap
- The distance between practices that have invested in modern clinical and digital systems and those that have not is widening every year, and the cost of closing it alone is now beyond most single-site operators.Operational
Sources: LaingBuisson, Dentistry UK Market Report, 7th ed., 18 September 2025; Christie & Co, Business Outlook 2026 — Dental, 15 January 2026; NHSBSA, NHS Dental Statistics for England 2025/26, 27 August 2026.
Where We Invest
Three categories, each assessed on its own terms.
Premium single sites
Individual practices with an established premium reputation, a strong private-patient base and a principal who wants the business to continue rather than be absorbed.
Established groups
Multi-site groups with proven management, consistent standards and further room to scale — where the constraint is capital and infrastructure rather than capability.
Defined upside
Well-run practices with quantifiable headroom — capacity, specialism or private conversion — where the plan to realise it can be written down before completion, not after.
Underwriting
Five dimensions. Every time.
No opportunity reaches the Investment Committee without a view on all five. A practice that is strong on four and weak on one is a conversation, not an offer.
- Clinical mix
- The balance, quality and durability of treatments provided, and their exposure to policy.
- Facilities & technology
- The standard of surgeries, equipment, premises and the systems the practice actually runs on.
- Regulatory standing
- CQC and GDC position, clinical records, indemnity, and the integrity of the compliance history.
- People
- The strength and stability of the clinical and support team, and the retention risk on completion.
- Quality of earnings
- The durability of underlying EBITDA, its dependence on the principal, and what survives their departure.
Value Creation
Where the return is actually made.
Four levers, in sequence. The first is arithmetic; the last three are work. Illustrative and indexed — not a forecast of any specific transaction.
Indexed illustration of the levers the Group intends to apply, shown at 100 = entry EBITDA. It is a description of method, not a projection, and carries no representation as to outcome. Multiple arbitrage between single-asset and platform valuations is deliberately excluded: it is a consequence of scale, not a lever management controls.
Process
From first conversation to completion.
Five stages. You can stop at any of them, and a number of conversations properly end at stage two — which is the point of running it this way.
Introduction, under NDA
A confidential conversation to understand the practice and, more importantly, what you want the transition to achieve. Nothing is shared beyond the immediate team.
Information exchange
We set out how DentLuxue works and what ownership within the Group means in practice. You share the operating and financial picture necessary to form a view.
Indicative offer
A written, non-binding indication setting out proposed structure and terms. Consideration is structured to the vendor’s objectives and the profile of the business; we do not publish a single template.
Due diligence
Legal, financial, clinical and regulatory diligence run by professional advisers to a defined timetable, structured to disturb the practice and its team as little as possible.
Completion & integration
Terms finalised, transaction completed, and integration led by people who have done it before — on a timeline agreed with you rather than imposed on you.
Horizon
Three phases, each underwritten by the last.
Foundation
2026 – 2028Complete the first acquisitions, codify the operating playbook, and stand up clinical governance and reporting across the initial estate.
Scale
2028 – 2031Expand practice count, deepen the technology layer across every site, and build a genuine multi-practice operating platform rather than a collection of clinics.
Platform leadership
2031 onwardEstablish DentLuxue as a recognised platform in UK premium dental care — built to be held and compounded, not dressed for a rapid onward sale.
Phasing describes present intention. It is a forward-looking statement, contingent on acquisitions not yet made and financing not yet committed, and no reliance should be placed upon it.
Considering a sale, now or within three years?
The earlier the conversation, the more of it you control.
Our Thesis
Why this market, why this structure, and what could go wrong.
This page sets out the Group’s reasoning and the principal risks to it. It is provided for general information about DentLuxue and its strategy. It is not an offer, an invitation, or an inducement to engage in investment activity of any kind.
The Opportunity
Fragmentation is not a slogan here. It is the arithmetic.
The UK high-street dental market was worth £12.16bn in 2023/24 and grew 9.2% year on year. Independent ownership still dominates it. Corporate buyers took only 7% of completions in 2025.
Three forces converge on UK dentistry at once. A generation of independent principals is approaching retirement with no obvious successor and valuations beyond associate reach. Sustained NHS access pressure continues to push steady demand toward private and mixed-economy care. And a widening gap has opened between practices that have invested in modern clinical and digital systems and those that have not.
Disciplined capital, deployed properly, sits at the intersection of all three. The scarce commodity is not money — it is an acquirer that a retiring principal is willing to hand a career to, with the operating capability to make the second five years better than the first.
Approach
How we intend to create value.
Disciplined underwriting
Every acquisition assessed on clinical quality and operational fundamentals against a written case, not on growth for its own sake. Practices are monitored after completion against the case on which they were approved.
Hands-on integration
Led by people who have completed it before, at scale, in this sector — over 350 acquisitions of oversight between the Chief Operating Officer and Chief Executive alone.
Technology as infrastructure
Early, real investment in the systems each practice runs on: clinical workflow, diagnostics, data. Deployed as infrastructure from the outset, not bolted on once the deal has closed.
Risk
Stated plainly, because they are real.
A thesis that lists no risks is marketing. These are the five that matter, and the Group’s view of each.
- Execution — the principal risk
- DentLuxue was incorporated on 9 September 2026 and has completed no acquisitions. The thesis is unproven until the first practices are acquired and integrated, and a board’s prior record is not the Group’s record.High
- Competition & regulatory review of private pricing
- On 2 April 2026 the Competition and Markets Authority opened a review of the private dentistry market, examining access, consumer choice, pricing, business conduct, redress and regulation. Any consolidator whose case rests on premium private pricing must assume that pricing, transparency and complaint handling will be scrutinised, and build to that standard now rather than later.Material
- NHS contract reform
- Reform and the political focus on access could reshape the economics of NHS-facing practices at short notice, in either direction. Mixed practices are underwritten on their private economics, with NHS income treated as an option rather than a foundation.Material
- Well-capitalised competition
- Experienced consolidators — among them myDentist, backed by Bridgepoint, and PortmanDentex — compete for the same assets with established origination and, in several cases, longer balance sheets. Corporate share of the pipeline is rising, which raises entry prices as well as opportunity.Ongoing
- Two simultaneous integrations
- Consolidating independent practices is operationally demanding by itself. Layering meaningful technology deployment on top adds a second, genuine execution challenge, and the two compete for the same management attention in the same window.Ongoing
Sources: Competition and Markets Authority market review of private dentistry, announced 2 April 2026; LaingBuisson, Dentistry UK Market Report, 7th ed., September 2025; Christie & Co, Business Outlook 2026, January 2026. Named competitors are identified for context only.
Questions about the Group or its strategy?
We are content to discuss the thesis and the team with serious counterparties.
Important. Nothing on this page or elsewhere on this website constitutes an offer or invitation to subscribe for or purchase any security, nor a financial promotion within the meaning of section 21 of the Financial Services and Markets Act 2000, nor any inducement to engage in investment activity. No securities of DentLuxue Holdings Limited are being offered by means of this website. Any such offer, if made, would be made only to eligible persons, by means of formal documentation, and in accordance with applicable law. Certain statements on this website are forward-looking and reflect present intention only; actual results may differ materially and no reliance should be placed upon them.
Careers
Build it, rather than inherit it.
DentLuxue is early. That is the offer and the risk in a single sentence: the people who join now shape what this becomes. We are interested in people who care about dentistry, about doing acquisitions properly, and about building something that outlasts its founders.
Disciplines
Where we are building teams.
- Clinical leadership
- Setting and safeguarding the standard every acquired practice operates to, and supporting the clinicians who deliver it.
- Operations & integration
- Taking a newly acquired practice from completion to a smoothly running part of the Group, without breaking what made it worth buying.
- Corporate, finance & legal
- Sourcing, structuring and closing acquisitions, and running the holding company to institutional standard.
- Technology & data
- Building and integrating the clinical and operational platforms every practice in the Group will run on.
Submit your candidacy.
We are not running fixed vacancies yet. Send a short note on why disciplined dental consolidation interests you, and we will ask for a CV if there is a conversation to be had. Brevity is a signal.
Contact
Start a conversation.
Practice principals, clinical partners, advisers and intermediaries. Enquiries are handled by the executive team directly and treated as confidential from the first message.
Registered office
Registered name
DentLuxue Holdings Limited
Registered in
England and Wales · Company number 17448083
Registered office
42–44 Bishopsgate
London EC2N 4AH
United KingdomIncorporated
9 September 2026
Correspondence
General enquiries
Practice principals & intermediaries
Careers
Press
Payment security. DentLuxue Holdings Limited will never notify a change of bank details by email. Any communication purporting to do so should be verified by telephone against a number obtained independently, before any payment is made.
Legal
Privacy Policy
1. Who we are
DentLuxue Holdings Limited (“DentLuxue”, “we”, “us”), a company registered in England and Wales under number 17448083, whose registered office is at 42–44 Bishopsgate, London EC2N 4AH, is the data controller for personal data collected through this website.
2. Information we collect
We collect information you provide directly — your name, organisation, email address and the content of your message — when you contact us through this site. Where you consent to them, we also collect limited technical and usage information via cookies and similar technologies, as described in our Cookie Policy.
3. How we use your information
- To respond to and progress enquiries, including from practice principals, advisers, clinical partners and candidates;
- To evaluate a specific opportunity or enquiry you have raised with us;
- To understand and improve how this website is used; and
- To comply with our legal and regulatory obligations.
4. Legal basis for processing
We rely on: your consent, where given (for example, for analytics cookies); our legitimate interests in responding to enquiries and operating this website; and, where relevant, steps necessary at your request prior to entering into a contract.
5. Sharing your information
We do not sell personal data. We may share information you provide with our professional advisers where necessary to evaluate a specific enquiry, and with service providers who help us operate this website, in each case subject to appropriate confidentiality and data processing obligations.
6. International transfers
Where personal data is transferred outside the United Kingdom, we take steps to ensure it receives an equivalent standard of protection, including through appropriate contractual safeguards.
7. Retention
We retain personal data only for as long as reasonably necessary for the purposes set out in this policy, or as required by law.
8. Your rights
Under the UK GDPR you have the right to request access to, rectification of, or erasure of your personal data; to restrict or object to our processing of it; and to data portability. To exercise any of these rights, contact enquiries@dentluxue.com.
9. Children
This website is directed at businesses and professional individuals. We do not knowingly collect personal data from children.
10. Changes
We may update this policy from time to time. Material changes will be reflected in the version and date shown above.
11. Contact and complaints
Questions may be sent to enquiries@dentluxue.com. You also have the right to lodge a complaint with the Information Commissioner’s Office at ico.org.uk.
Legal
Terms of Use
1. Acceptance
By accessing or using this website you agree to be bound by these Terms of Use. If you do not agree, please do not use this website.
2. Who operates this website
This website is operated by DentLuxue Holdings Limited, a private company registered in England and Wales under number 17448083, whose registered office is at 42–44 Bishopsgate, London EC2N 4AH, United Kingdom.
3. Purpose — and what this website is not
This website is provided for general information about DentLuxue Holdings, its strategy, its leadership and how to make contact. Nothing on it constitutes an offer or invitation to subscribe for or purchase any security, a financial promotion within the meaning of section 21 of the Financial Services and Markets Act 2000, or an inducement to engage in investment activity.
4. No professional advice
Nothing on this website constitutes legal, financial, tax, clinical or investment advice. You should obtain independent professional advice before acting in reliance on anything published here.
5. Forward-looking statements
Certain statements on this website concerning intentions, plans, phasing and objectives are forward-looking. They reflect present expectation only, are subject to risks and uncertainties including those described on the Our Thesis page, and actual outcomes may differ materially. No reliance should be placed upon them.
6. Intellectual property
Unless otherwise stated, the DentLuxue name, mark and logo, and the content, design and layout of this website, are the property of DentLuxue Holdings Limited or its licensors and may not be reproduced without prior written consent.
7. Accuracy
We take reasonable care to keep this website accurate and current. Third-party data is attributed to its source and stated as at the date of that source. We do not warrant that all information is complete, accurate or up to date and, to the extent permitted by law, accept no liability for any error or omission.
8. Third-party links
This website may contain links to third-party websites. We are not responsible for the content or privacy practices of any website we do not operate.
9. Limitation of liability
To the fullest extent permitted by law, DentLuxue Holdings Limited excludes all liability for any loss or damage arising from your use of, or inability to use, this website. Nothing in these terms excludes liability for death or personal injury caused by negligence, or for fraud or fraudulent misrepresentation.
10. Governing law
These terms are governed by the laws of England and Wales, and the courts of England and Wales shall have exclusive jurisdiction.
11. Contact
Questions may be sent to enquiries@dentluxue.com.
Legal
Cookie Policy
1. What cookies are
Cookies are small files placed on your device when you visit a website. They help a site function and, where you consent, help the operator understand how it is used.
2. What this website uses
- Strictly necessary — required for the website to operate and to record your cookie preference. These cannot be switched off and do not require consent.
- Analytics — set only where you have consented, to understand how visitors use this site so that we can improve it.
3. Advertising and profiling
We do not use advertising cookies or third-party profiling cookies on this website.
4. Managing your preferences
On your first visit you may accept all cookies or essential cookies only. Your choice is stored on your device and is respected on return. You may also control or delete cookies at any time through your browser settings.
5. Changes
We may update this policy to reflect changes in the cookies we use.
6. Contact
Questions may be sent to enquiries@dentluxue.com.